Joseph Palumbo

1.9k total citations
45 papers, 1.3k citations indexed

About

Joseph Palumbo is a scholar working on Psychiatry and Mental health, Neurology and Pharmacology. According to data from OpenAlex, Joseph Palumbo has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Psychiatry and Mental health, 17 papers in Neurology and 14 papers in Pharmacology. Recurrent topics in Joseph Palumbo's work include Schizophrenia research and treatment (14 papers), Amyotrophic Lateral Sclerosis Research (11 papers) and Attention Deficit Hyperactivity Disorder (8 papers). Joseph Palumbo is often cited by papers focused on Schizophrenia research and treatment (14 papers), Amyotrophic Lateral Sclerosis Research (11 papers) and Attention Deficit Hyperactivity Disorder (8 papers). Joseph Palumbo collaborates with scholars based in United States, Japan and Australia. Joseph Palumbo's co-authors include Srihari Gopal, Pilar Lim, Vivek Kusumakar, Eric Yuen, Cristiana Gassmann-Mayer, Joris Berwaerts, Lawrence H. Price, Keith Karcher, Larry Alphs and Mahesh N. Samtani and has published in prestigious journals such as American Journal of Psychiatry, Neurology and Biological Psychiatry.

In The Last Decade

Joseph Palumbo

43 papers receiving 1.3k citations

Peers

Countries citing papers authored by Joseph Palumbo

Since Specialization

Citations

This map shows the geographic impact of Joseph Palumbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Palumbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Palumbo more than expected).

Fields of papers citing papers by Joseph Palumbo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Palumbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Palumbo. The network helps show where Joseph Palumbo may publish in the future.

Co-authorship network of co-authors of Joseph Palumbo

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Palumbo. A scholar is included among the top collaborators of Joseph Palumbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Palumbo. Joseph Palumbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease 2025 ·Frontiers in Neuroscience ·Christopher L. Reading, Jiayan Yan, Marcia A. Testa, Donald C. Simonson, (unknown), (unknown), Daniel E. Martin‐Herranz, Robert T. Brooke, Juozas Gordevičius, Jeffrey Zhang, (unknown), Clarence Ahlem, Lixia Wang, (unknown), Noor Azuan Abu Osman, Stephen O’Quinn, Joseph Palumbo	1
2	Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day—A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia 2025 ·Psychopharmacology Bulletin ·Danielle Coppola, Rama Melkote, (unknown), Jaskaran Singh, Isaac Nuamah, Srihari Gopal, David M. Hough, Joseph Palumbo	3
3	Metabolic dysregulation in a phase 3, placebo-controlled, randomised study of NE3107 (bezisterim) in subjects with probable Alzheimer’s disease 2023 ·Neuroscience Applied ·Christopher L. Reading, Clarence Ahlem, Joseph Palumbo, Marcia A. Testa, Suzanne de la Monte, Donald C. Simonson	1
4	Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment 2023 ·Journal of Neurodevelopmental Disorders ·Joseph Palumbo, Brian F. Thomas, Dejan B. Budimirovic, Steven J. Siegel, Flora Tassone, Randi J. Hagerman, Christopher Faulk, Stephen O’Quinn, Terri Sebree	13
5	A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX) 2022 ·Journal of Neurodevelopmental Disorders ·Elizabeth Berry‐Kravis, Randi J. Hagerman, Dejan B. Budimirovic, Craig A. Erickson, Helen Heussler, Nicole Tartaglia, Jonathan Cohen, Flora Tassone, (unknown), Elizabeth Merikle, Terri Sebree, (unknown), Joseph Palumbo, Stephen O’Quinn	39
6	PRO1 Meaningful Change Thresholds for the Aberrant Behavior Checklist-Community Fragile X Syndrome (ABC-CFXS) in Children and Adolescents with FXS 2021 ·Value in Health ·Elizabeth Merikle, (unknown), Timothy Dobbins, (unknown), (unknown), Terri Sebree, Randi J. Hagerman, Joseph Palumbo	1
7	ST1 Caregiver-Perceived Behavioral Challenges in Fragile X Syndrome (FXS) and Their Measurement Using the Aberrant Behavior Checklist-Community FXS Specific (ABC-CFXS) 2021 ·Value in Health ·Elizabeth Merikle, (unknown), (unknown), Terri Sebree, Randi J. Hagerman, Joseph Palumbo	1
8	A Long-Term Safety and Efficacy Extension Study of Patients Diagnosed with Amyotrophic Lateral Sclerosis (ALS) and Treated with Edaravone (MCI-186) (P3.192) 2016 ·Neurology ·Takeshi Sakata, Joseph Palumbo, Makoto Akimoto, Masahiko Tanaka	4
9	Sustained Efficacy for up to 12 Months in an Active Extension of a Phase III Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS) (P3.190) 2016 ·Neurology ·Joseph Palumbo, Takeshi Sakata, Masahiko Tanaka, Makoto Akimoto	1
10	A Double-Blind, Parallel-Group, Placebo-Controlled, 24-Week, Exploratory Study of Edaravone (MCI-186) for the Treatment of Advanced Amyotrophic Lateral Sclerosis (ALS) (P3.191) 2016 ·Neurology ·Masahiko Tanaka, Makoto Akimoto, Joseph Palumbo, Takeshi Sakata	5
11	The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders 2011 ·Neuropsychopharmacology ·(unknown), Raymond F. Anton, Raye Z. Litten, Daniel E. Falk, Joseph Palumbo, Raymond T. Bartus, R.L. Robinson, Henry R. Kranzler, Thomas R. Kosten, Roger E. Meyer, Charles P. O’Brien, Karl Mann, Didier Meulien	25
12	Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder 2010 ·Biological Psychiatry ·Jorge A. Quiroz, Lakshmi N. Yatham, Joseph Palumbo, Keith Karcher, Stuart Kushner, Vivek Kusumakar	104
13	One-Year Open-Label Safety and Efficacy Study of Paliperidone Extended-Release Tablets in Patients With Schizophrenia 2010 ·CNS Spectrums ·Michelle Kramer, George M. Simpson, Valentinas Mačiulis, Stuart Kushner, Yanning Liu, Pilar Lim, David Hough, Joseph Palumbo, Mariëlle Eerdekens	11
14	A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia 2010 ·Journal of Clinical Psychopharmacology ·Gahan Pandina, Jean‐Pierre Lindenmayer, (unknown), Pilar Lim, Srihari Gopal, Virginie M.M. Herben, Vivek Kusumakar, Eric Yuen, Joseph Palumbo	159
15	A randomized, placebo‐ and active‐controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder 2010 ·Bipolar Disorders ·Eduard Vieta, Isaac Nuamah, Pilar Lim, Eric Yuen, Joseph Palumbo, David Hough, Joris Berwaerts	71
16	Efficacy and Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder 2009 ·Journal of Clinical Psychopharmacology ·Lenard A. Adler, Brenda Zimmerman, H. Lynn Starr, (unknown), Joseph Palumbo, Camille Orman, Thomas Spencer	84
17	Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies 2008 ·International Clinical Psychopharmacology ·Robin Emsley, Joris Berwaerts, Mariëlle Eerdekens, Michelle Kramer, Rosanne Lane, Pilar Lim, David M. Hough, Joseph Palumbo	69
18	An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder 2005 ·International Clinical Psychopharmacology ·Robert M. A. Hirschfeld, Mariëlle Eerdekens, Amir H Kalali, Carla M. Canuso, Akbar Ali Khan, Keith Karcher, Joseph Palumbo	32
19	Regional cerebral blood flow during acute and chronic abstinence from combined cocaine–alcohol abuse 1998 ·Drug and Alcohol Dependence ·Thomas R. Kosten, (unknown), Joseph Palumbo, John Seibyl, Lawrence H. Price, Scott W. Woods	34
20	Dopaminergic responsivity during cocaine abstinence: a pilot study 1992 ·Psychiatry Research ·Christopher J. McDougle, Lawrence H. Price, Joseph Palumbo, Thomas R. Kosten, George R. Heninger, Herbert D. Kleber	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact